Robin Hofmann

[European Society of Cardiology Journals @ESC_Journals]

A strain on the diagnosis https://t.co/Hx6SKU307Y

#EHJCaseReports #echofirst @KardiologieHH @aayshacader @TJ_Yeo @ANazmiCalik @FarhanaAra @cfcamm @EHJCREiC

[Robin Hofmann @Robodoc2013]

No difference i HRQoL with regard to beta-blocker dose post MI: https://t.co/JCmJKcpZDa

[EuroIntervention @EuroInterventio]

Using contemporary data from nationwide population-based registries, this study showed early discharge (i.e., within 2 days of admission) to be safe in low-risk patients with STEMI treated with primary PCI. #EAPCI https://t.co/9qOEKT1C69

[Robin Hofmann @Robodoc2013]

MI treatment: Spend your money and time for more effective treatments: Cost analysis from the DETO2X-SWEDEHEART trial: https://t.co/vk9HCChrM4

[Troels Yndigegn MD PhD @YndigegnY]

-> All MI patients will be routinely screened for H. pylori:
-> Patients diagnosed with active H. pylori infection will receive eradication therapy
-> All follow-up by data collection from national registries.

https://t.co/Y0EYsbOXkc

[Robin Hofmann @Robodoc2013]

@GreggWStone From SWEDEHEART, we are trying to shed some light on the related issue of the impact of Helicobacter pylori infection and treatment on upper GI bleeding post MI: the HELP-SWEDEHEART trial started enrolling Nov 17: https://t.co/9p0IGlYMRb

[Robin Hofmann @Robodoc2013]

@GreggWStone Very interesting study, thank you! The gastrocardiac syndrome is more relevant than ever! https://t.co/pMYzjX2RvU

[Robin Hofmann @Robodoc2013]

@psirides @proftomquinn @ajburls http://t.co/LBpaxR7FXw

[Robin Hofmann @Robodoc2013]

@psirides @proftomquinn @ajburls thanks. Still a bit of waiting but >50% is a start! '16 we'll know more, maybe some biomarkers before...

[Robin Hofmann @Robodoc2013]

@proftomquinn No worries Prof - Robodoc is watching the scene. It seems under control. Very competend surrogate! Deto2xyfied cheers!